Thoughts on AstraZeneca’s Acquisition of Neogene

On Tuesday, November 29, AstraZeneca announced (press release) an agreement to acquire Neogene Therapeutics for the development of TCR-T therapies in solid tumors. Below, Celltelligence provides insights on AstraZeneca’s increasing interest in the cell therapy space, while discussing Neogene’s potential competitors.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.